Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    TopAbstracts in Hypertension 12/02/2009 - (DGNews)
    Obesity Leading Risk Factor of Left Atrial Enlargement During Aging - (DGNews)
    TopAbstracts in Hypertension 11/25/2009 - (DGNews)
    Team-Based Care Involving a Pharmacist Improves Blood Pressure Control - (DGNews)
    Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study - (BMJ)

    News archive

     Recent webcasts/CME - Hypertension
    • State of the Art in Pulmonary Arterial Hypertension
    • Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Optimizing Antihypertensive Therapy and Health and Economic Outcomes in a Managed Care Environment
      Treating Coronary Artery Disease in Vulnerable Adults
      Thrombotic Thrombocytopenic Purpura: The Masquerader

      Webcasts/CME archive

       Recent cases - Hypertension
        A Woman with Swollen Fingers and New-Onset Hypertension and Renal Failure
        Hypertension
        Medical Management of a Pregnancy Woman with Moderate Renal Insufficiency and Superimposed Preclampsia
        Malignant Hypertension and Acute Aortic Dissection Associated with Caffeine-Based Ephedra-Free Dietary Supplements: A Case Report
        Giant Right Coronary Artery Aneurysm: Case Report and Literature Review

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Eplerenone and Enalapril Equally Effective as Monotherapy for Hypertension, but Eplerenone Produces Greater Reduction in Albuminuria

        A DGReview of :"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension"
        American Journal of Cardiology

        04/27/2004
        By Keely S. Solomon, Ph.D.


        Eplerenone is as effective and safe as is enalapril for the treatment of hypertension, and is more effective in reducing albuminuria, according to a recent American study.

        Eplerenone is a steroid nucleus-based anti-mineralocorticoid that has been shown to effectively reduce blood pressure (BP) when administered as monotherapy in the dose range of 25 to 200 mg/day. However, long-term studies of the efficacy of eplerenone have not previously been reported.

        Researchers led by Gordon H. Williams, MD, of the Brigham and Women's Hospital, Boston, Massachusetts, and colleagues performed a 12-month study to compare the efficacy and safety of eplerenone with enalapril, an angiotensin converting-enzyme (ACE) inhibitor.

        Patients were randomised with 253 receiving eplerenone (40.7% females, mean age=54.7) and 246 receiving enalapril (48.8% females, mean age=55.7) for a 6-month period. Starting doses were 50 mg eplerenone or 10 mg enalapril. Doses could be subsequently doubled up to 2 times if the diastolic BP was not lower than 90 mm Hg at 4, 8 or 12 weeks. After 6 months, dosages reduced by half and were followed for an additional 6 months in patients who achieved a diastolic BP lower than 90 mm Hg.

        The 2 treatment groups showed similar reductions at 6 months in both systolic BP (eplerenone, -14.5 mm Hg; enalapril, -12.7 mm Hg; P = .199) and diastolic BP (eplerenone, -11.2 mm Hg; enalapril, -11.3 mm Hg; P = .910), and the improvements remained comparable between the groups at 12 months (eplerenone, -16.5/-13.3 mm Hg, p=.251; enalapril, -14.8/-14.1 mm Hg, P = .331). BP response showed a significant correlation with baseline renin levels in the enalapril group, as expected for an ACE inhibitor, whereas no correlation was detected in the eplerenone group. Both treatments reduced albuminuria in patients with elevated levels at baseline, but the improvement was significantly greater in the eplerenone group (-61.5% vs. 25.7%, P = .01).

        "These results suggest that the mechanism of action of eplerenone in lowering BP may not be entirely due to diuresis but may also be associated with effects of blocking mineralocorticoid receptors in the brain and vasculature," the researchers write.

        The 2 treatments were similarly well tolerated, and the researchers report comparable withdrawal rates for adverse events (at 6 months: eplerenone 7.9%, enalapril 9.3%) and treatment failures (at 6 months: eplerenone 23.3%, enalapril 22.8%). Two patients taking eplerenone and 2 taking enalapril experienced hyperkalemia of 5.5 mmol/L or more, but no patient had an elevated potassium level of greater than 6.0 mmol/L.

        "This study demonstrates that eplerenone is as effective as enalapril for monotherapy in patients with stage 1 or 2 hypertension regardless of their renin level, is more effective in reducing albuminuria, and is well tolerated up to 12 months," the researchers conclude.










        Am J Cardiol 2004 Apr 15;93:8:990-6. "Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send